Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tocagen Inc.

www.tocagen.com

Latest From Tocagen Inc.

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?

Financing Business Strategies

Pipeline Watch: Patisiran, Etrolizumab, ALKS8700 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

IPO Update: New Offerings Outperform As September Ends With Biopharma Trifecta

There have been 29 IPOs in the US through the third quarter of 2017 with an average return of 35.2%, including three offerings on the same day – Deciphera, Nightstar and NuCana – near the end of September.

Financing Business Strategies

2017 IPOs In Review: US Biopharma Offerings Rise, Values Decline At Mid-Year

Nineteen biopharma firms went public in the US during the first half of 2017, but as the number of IPOs increased, the average return on first-time offerings decreased, raising a key question: can this pace of first-time offerings continue in the second half?

Commercial Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tocagen Inc.
  • Senior Management
  • Martin Duvall, CEO
    Mark G Foletta, EVP, CFO
    Lori Kunkel, MD, Acting CMO
    Nicholas A Boyle, PhD, VP, Bus. Dev. & Mktg.
    Fairooz Kabbinavar, SVP, Clinical Dev.
  • Contact Info
  • Tocagen Inc.
    Phone: (858) 412-8400
    4242 Campus Point Ct.
    Ste. 500
    San Diego, CA 82121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register